Warsaw

• A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EF … Ended
  2025-521508-23-00 3 2025-10-10 Adrenoleukodystrophy
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and p … Ended
  2025-521451-23-00 5 2025-09-03 Subjects scheduled for elective colonoscopy performed according to ESG
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• clinical trial evaluating the efficacy of nintedanib with tocilizumab compared to standard treatment in patients with systemic sclerosis and … Ended
  2024-517005-85-00 5 2025-07-01 systemic sclerosis with interstitial lung disease (ILD) in the course
• A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended
  2023-508759-38-00 1 2025-06-04 Relapsed/Refractory B-cell Malignancies
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation … Ended
  2024-514725-38-00 2 2025-05-26 Maintenance bronchodilator treatment to relieve symptoms in adult pati
• The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinic … Ended
  2023-505875-56-00 6 2025-05-21 Knee osteoarthritis
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder … Ended
  2024-511549-20-00 4 2025-04-22 Dermatitis atopic
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 Rheumatoid Arthritis
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with … Ended
  2024-514562-40-00 4 2025-03-13 Hidradenitis suppurativa (HS)
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended
  2024-511261-11-00 4 2025-03-05 Respiratory tract diseases
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract … Ended
  2023-506138-65-00 6 2025-02-20 Heart failure with preserved ejection fraction
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 5 2024-12-23 Ataxia Telangiectasia (A-T)
• Once-weekly petrelintide versus placebo for obesity or overweight with comorbidities Ended
  2024-512549-18-00 4 2024-12-19 Weight management
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 5 2024-12-17 Rheumatoid arthritis

Showing 1,297–1,320 of 1,708 trials